Peiliang Dong

Peiliang Dong


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2025 in Metabolic Brain Disease
Verified
Journal Article
Closed access
XLXintong Li
Xintong Li
MYMeng Yang
Meng Yang
TWTiantian Wang
Tiantian Wang
SLSiyu Liu
Siyu Liu
HHHua Han
Hua Han
PDPeiliang Dong
Peiliang Dong

16 September 2024 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
MWMingtao Wang
Mingtao Wang
XZXinyue Zheng
Xinyue Zheng
MYMeng Yang
Meng Yang
JNJiating Ni
Jiating Ni
QXQian Xiao
Qian Xiao
PDPeiliang Dong
Peiliang Dong

3 January 2024 in Psychogeriatrics
Verified
Journal Article
Closed access
QCQingyu Cao
Qingyu Cao
PDPeiliang Dong
Peiliang Dong
HHHua Han
Hua Han

28 August 2025 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
XZXinyue Zheng
Xinyue Zheng
WLWenwen Li
Wenwen Li
MWMingtao Wang
Mingtao Wang
HGHaiyi Gao
Haiyi Gao
YZYian Zhao
Yian Zhao
HHHua Han
Hua Han

10 April 2024 in Journal of Chromatography B
Verified
Journal Article
Closed access
PCPengyi Chen
Pengyi Chen
CPChengguo Pang
Chengguo Pang
LBLincheng Bai
Lincheng Bai
YZYulong Zhang
Yulong Zhang
PDPeiliang Dong
Peiliang Dong
HHHua Han
Hua Han

10 November 2023 in Heliyon
Verified
Journal Article
Open access
XYXu Yuan
Xu Yuan
KLKemeng Liu
Kemeng Liu
PDPeiliang Dong
Peiliang Dong
HHHua Han
Hua Han
This study aims to investigate the protective effect and mechanism of "Danggui-Kushen" herb pair (DKHP) on ischemic heart disease (IHD). The rat model of myocardial reperfusion injury (MIRI) was established by ligation of the left anterior descending coronary artery. Rats were randomly divided into seven groups and administered orally for 7 days: control group, IHD group, DKHP1:1 group, DKHP1:2 group, DKHP2:1 group, DKHP1:3 group, DKHP3:1 group, the dosage was 2.7 g/kg. Measure electrocardiogram (ECG), myocardial infarction and injury assessment, Hematoxylin and eosin (HE) staining to evaluate myocardial injury and the protective effect of DKHP. Lactate dehydrogenase (LDH), Reactive oxygen species (ROS), IL-1β and IL-6 kit detection, immunohistochemical analysis, establishment of H9c2 cardiomyocyte hypoxia (Hypoxia) model, DKHP pretreatment for 3 h, MTT method to detect cell survival rate, cell immunofluorescence to observe NF- The expression of TLR-4, NF-κB, p-NF-κB, IKβα, p-IKβα, HIF-1α, VEGF and other genes and proteins were detected by κB nuclear translocation, mitochondrial membrane potential measurement, Western blot and Polymerase Chain Reaction (PCR). Compared with the model group, DKHP can reduce the size of myocardial infarction, reduce the levels of factors such as LDH, ROS, IL-1β and IL-6, and improve the cell survival rate; Compared with the model group, DKHP can inhibit the nuclear transfer of NF-κB and reduce mitochondrial damage; the results of immunohistochemical analysis, PCR and Western blot showed that compared with the model group, DKHP can reduce TLR-4, p-NF-κB, Expression levels of p-IKβα, HIF-1α, VEGF and other proteins. Reveal that DKHP may play a protective role in ischemic heart disease by reducing inflammation and oxidative stress damage. DKHP may have protective effect on ischemic heart disease, and its mechanism may be through reducing inflammatory response and oxidative stress damage to achieve this protective effect.